Validated GMP banking of a new set of genomically stable induced pluripotent stem cell lines using single-cell passaging

Cytotherapy 2026 Open access

Read full text
Authors: Björn Hiller, François Hafezi, Jens Lichte, Noah Henschel, Claudia Träger, Melanie Hühne, Anna Gamerschlag, Thomas Berger, Soraia Martins, Daniel Terheyden-Keighley, Elitsa Borisova, Davood Sabour
+4 more Agnes Beermann, Gesine Kögler, Andrea Meffert, Boris Greber
DOI: 10.1016/j.jcyt.2026.102120
Cited by: 0
References: 15

Abstract

Single-cell passaging of induced pluripotent stem cells (iPSCs) has historically been discredited, as it may risk mutations. Here, however, in combination with Rho kinase inhibition and based on stringent quality control, we successfully validate a corresponding iPSC banking process under Good Manufacturing Practice (GMP) conditions. The underlying culture system features enhanced consistency, sustains genomic integrity in the resulting cell lines, and enables excellent priming for gene editing and directed differentiation. The process, as well as the resulting GMP iPSC lines, will provide a robust foundation for clinical manufacturing.

Fields of Study & Subjects

Pluripotent Stem Cells Research CRISPR and Genetic Engineering Mesenchymal stem cell research

Publication details

Journal / source
Cytotherapy
Volume
28
Issue
6
Pages
102120–102120
Publication date
24 February 2026
Language
EN